【摘要】 目的评价来曲唑联合紫杉醇及卡铂治疗复发性子宫内膜癌的近期疗效及毒副作用。方法回顾性分析我院2013年1月～2015年12月间采用来曲唑联合紫杉醇及卡铂治疗复发子宫内膜癌的患者。在本研究中,共35例患者,按照1:1的比例对两组进行随机分组。对照组行紫杉醇和卡铂的联合化疗。每3周一次。实验组入组后立即开始长期口服来曲唑,每日2.5 mg,直到化疗结束停止。同时行上述标准的紫杉醇和卡铂联合化疗。每3周一次。观察肿瘤标记物CA125、HE4变化情况、毒性反应评分、生活质量评分等,复发时间、肿瘤无进展间期、复发率、1年、2年和3年生存率。结果共行化疗188个疗程,实验组的6个月、12个月、18个月、24个月、30个月及36个月生存率分别为100.00%、88.89%、77.78%、61.11%、50.00%、38.89%。对照组的6个月、12个月、18个月、24个月、30个月及36个月生存率分别为100.00%、82.35%、64.71%、47.06%、29.41%、17.65%。实验组生存时间明显高于对照组,差异有统计学意义(P<0.05)。实验组有效率高于对照组。毒性反应是基于紫杉醇的严重过敏毒性反应,其次是紫杉醇联合卡铂的骨髓抑制及少数患者的潮热、盗汗等。结论实验组较对照组在治疗复发子宫内膜癌时有较高的疗效,无明显增加毒副反应。其在改善患者生存质量,延长患者生存周期方面更加优越。更多还原

【Abstract】 Objective To evaluate the short-term efficacy and side effects of letrozole combined with paclitaxel and carboplatin in the treatment of recurrent endometrial cancer. Methods The patients with recurrent endometrial cancer treated with letrozole combined with paclitaxel and carboplatin in our hospital from January 2013 to December 2015 were retrospectively analyzed. In this study, a total of 35 patients were randomized into two groups at a 1:1 ratio. The control group was given combination chemotherapy of paclitaxel and carboplatin, once per three weeks. The experimental group was given long-term oral letrozole immediately after enrollment, 2.5 mg daily until the end of chemotherapy, and also given the above standard combination chemotherapy of paclitaxel and carboplatin, once per three weeks. The tumor markers CA125, HE4 changes, toxicity scores, quality of life scores, recurrence time, tumor progression-free interval,recurrence rate, 1-year, 2-year, and 3-year survival rates were observed. Results A total of 188 courses of chemotherapy were performed. The survival rates of the experimental group at 6 months, 12 months, 18 months, 24 months,30 months and 36 months were 100.00%, 88.89%, 77.78%, 61.11%, 50.00%, 38.89%, respectively.The 6-month, 12-month, 18-month, 24-month, 30-month, and 36-month survival rates of the control group were 100.00%, 82.35%,64.71%, 47.06%, 29.41%, and 17.65%, respectively. The survival time of the experimental group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05). The experimental group was more effective than the control group. Toxic reaction was based on severe allergic toxicity of paclitaxel, followed by myelosuppression of paclitaxel combined with carboplatin, and hot flashes and night sweats in a small number of patients. Conclusion The experimental group has higher effect than the control group in the treatment of recurrent endometrial cancer and has no significantly increased toxic side effects. It is superior in improving the quality of life of patients and prolonging the life cycle of patients.更多还原